1. Scrip
  2. >>Business

Novel Regeneron Deal Puts Partner Decibel In The Driver's Seat

 
• By Jessica Merrill and Mandy Jackson

Regeneron signed a unique agreement with the hearing-focused start-up Decibel in which it will make a minority equity investment and pay R&D costs, but leave full commercialization rights with its partner. The deal sprang from Regeneron’s outreach to venture-backed biotechs.

Hands

Regeneron Pharmaceuticals Inc. is looking for ways to put its vast drug discovery and development machinery to work on behalf of start-ups that don't have the resources to build those capabilities on their own. Through that effort, it negotiated a novel collaboration with hearing-focused Decibel Therapeutics.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Biotech Leaders Fear FDA Disruption Is Causing Delays

 
• By Jessica Merrill

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.